Efficacy and safety of Agomelatine (25 mg with potential adjustment at 50 mg) given orally once a day for 12 weeks in out-patients with Generalised Anxiety Disorder. A randomised flexible dose double-blind, placebo-controlled, parallel groups, international study.
Phase of Trial: Phase II
Latest Information Update: 06 Sep 2011
At a glance
- Drugs Agomelatine (Primary)
- Indications Generalised anxiety disorder
- Focus Therapeutic Use
- 06 Sep 2011 Status changed from recruiting to completed based on reported results.
- 07 Jul 2011 New trial record